A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor

Author:

Chen Michael1ORCID,Sheu Ming-Thau2,Cheng Tian-Lu34ORCID,Roffler Steve R.5,Lin Shyr-Yi678,Chen Yi-Jou1,Cheng Yi-An4ORCID,Cheng Jing-Jy79,Chang Hsin-Yu1,Wu Tung-Yun10ORCID,Kao An-Pei11,Ho Yuan-Soon81213,Chuang Kuo-Hsiang13101415

Affiliation:

1. Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan

2. School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan

3. Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan

4. Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung City, Taiwan

5. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

6. Department of Primary Care Medicine, Taipei Medical University Hospital, Taipei, Taiwan

7. Department of General Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

8. TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan

9. National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan

10. Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan

11. Stemforce Biotechnology Co., Ltd, Chiayi City, Taiwan

12. School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

13. Cancer Research Center, Taipei Medical University Hospital, Taipei, Taiwan

14. Traditional Herbal Medicine Research Center of Taipei Medical University Hospital, Taipei, Taiwan

15. Ph.D Program in Biotechnology Research and Development, Taipei Medical University, Taipei, Taiwan

Abstract

Clinical nanoparticles were armed with TsAb through a one-step non-covalent modification to achieve the maximal specific killing against TAF-rich solid tumors.

Funder

Ministry of Science and Technology, Taiwan

National Health Research Institutes

Ministry of Education

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3